In Muted Hearing, Pharma Execs Dodge Attempts to Pin Blame for High Prices

February 26, 2019

(STAT News) – The hearing had all the makings of a high-profile Washington event, complete with lines snaking out the door, full of people paid by lobbyists to hold their place, and cameras flashing in executives’ faces. But the executives from seven pharmaceutical manufacturers — Merck, Pfizer, AstraZeneca, Johnson & Johnson, AbbVie, Sanofi, and Bristol-Myers Squibb — largely dodged the tougher lines of questioning from the panel’s mostly staid members. They pivoted, again and again, to well-worn lines of defense about the promise of innovation and new cures.

Recommended Reading